Lisa Eidenschink Brodersen
Overview
Explore the profile of Lisa Eidenschink Brodersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Menssen A, Hudson C, Alonzo T, Gerbing R, Pardo L, Leonti A, et al.
Haematologica
. 2024 Feb;
109(10):3182-3193.
PMID: 38299667
As curative therapies for pediatric acute myleoid leukemia (AML) remain elusive, identifying potential new treatment targets is vital. We assessed the cell surface expression of CD74, also known as the...
2.
Hsu F, Hudson C, Wilson E, Pardo L, Singleton T, Xu D, et al.
Cytometry B Clin Cytom
. 2023 Apr;
104(4):311-318.
PMID: 37015883
Background: Detection of measurable residual disease detection (MRD) by flow cytometry after the first course of chemotherapy is a standard measure of early response in patients with acute myeloid leukemia...
3.
Comprehensive molecular and clinical characterization of fusions in pediatric acute myeloid leukemia
Bertrums E, Smith J, Harmon L, Ries R, Wang Y, Alonzo T, et al.
Haematologica
. 2023 Feb;
108(8):2044-2058.
PMID: 36815378
NUP98 fusions comprise a family of rare recurrent alterations in AML, associated with adverse outcomes. In order to define the underlying biology and clinical implications of this family of fusions,...
4.
Kern W, Westers T, Bellos F, Bene M, Bettelheim P, Brodersen L, et al.
Cytometry B Clin Cytom
. 2022 Nov;
104(1):51-65.
PMID: 36416672
Background: Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia...
5.
Kirkey D, Loeb A, Castro S, McKay C, Perkins L, Pardo L, et al.
Blood Adv
. 2022 Aug;
7(7):1178-1189.
PMID: 35984639
Preferentially Expressed Antigen in Melanoma (PRAME), a cancer-testis antigen, provides an ideal target for immunotherapy in acute myeloid leukemia (AML). We have shown expression of PRAME in a significant subset...
6.
Rosenzweig J, Pillai P, Prockop S, Benayed R, Brodersen L, Najfeld V, et al.
Cold Spring Harb Mol Case Stud
. 2022 Apr;
8(3).
PMID: 35483876
Myeloid leukemia of Down syndrome (ML-DS) in young children is associated with distinct clinical and biological features and is typically initiated with oncogenic mutations in the X-linked megakaryocytic transcription factor...
7.
Pollard J, Alonzo T, Gerbing R, Brown P, Fox E, Choi J, et al.
J Clin Oncol
. 2022 Mar;
40(18):2023-2035.
PMID: 35349331
Purpose: High allelic ratio (HAR) /ITD (AR > 0.4) mutations confer poor prognosis in pediatric acute myeloid leukemia (AML). COG AAML1031 studied the feasibility and efficacy of adding sorafenib, a...
8.
Lamble A, Brodersen L, Alonzo T, Wang J, Pardo L, Sung L, et al.
J Clin Oncol
. 2021 Dec;
40(3):252-261.
PMID: 34855461
Purpose: Increased CD123 surface expression has been associated with high-risk disease characteristics in adult acute myeloid leukemia (AML), but has not been well-characterized in childhood AML. In this study, we...
9.
Cutler J, Pugsley H, Bennington R, Fritschle W, Hartmann L, Zaidi N, et al.
Cytometry B Clin Cytom
. 2021 Nov;
104(2):183-194.
PMID: 34773362
Background: Myelodysplastic syndromes (MDS) are a heterogenous collection of clonal bone marrow diseases characterized by cytopenias, abnormal karyotypes, molecular abnormalities, and dysplasia by flow cytometry and/or morphology. The progression of...
10.
Elgarten C, Wood A, Li Y, Alonzo T, Brodersen L, Gerbing R, et al.
Pediatr Blood Cancer
. 2021 Oct;
68(12):e29281.
PMID: 34596937
Background: High-risk pediatric acute myeloid leukemia confers a poor prognosis, and alternative strategies are needed to improve outcomes. We hypothesized that intensifying induction on the AAML1031 clinical trial would improve...